Molecularly Targeted Vaccines for Anthrax

炭疽分子靶向疫苗

基本信息

  • 批准号:
    7187390
  • 负责人:
  • 金额:
    $ 101.09万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-08-15 至 2011-01-31
  • 项目状态:
    已结题

项目摘要

Inhalation anthrax has emerged as a significant and continuing biowarfare and bioterrofism threat. Though vaccine strategies have substantially controlled this disease in animal populations, the current vaccine licensed for human use has several shortcomings including significant adverse reactions and low immunogenicity resulting in the need for multiple immunizations. The biology of anthrax infection and specifically the actions of its toxins have been elegantly elucidated at the molecular and cellular level. This presents a unique opportunity to rationally designed and develop an improved vaccine that can counter current anthrax as well as modified forms that may be encountered in the future. In this project we will use the substantial body of knowledge and insight available relating to anthrax toxin to develop molecularly targeted vaccines to prevent the catastrophic effects of toxin following infection. Based on careful analysis of the crystal structure, sequence, and functional studies of all components of the anthrax toxins, we will develop soluble protein vaccines that direct antibody responses towards the critical protein segments involved in toxin activation, assembly, and adherence to cells. We will test these vaccine constructs for their ability to elicit strong antibody responses with the ability to neutralize toxin activity in in vitro assays. Based on analysis of responses to the soluble protein constructs, selected constructs will be moved into the adeno-associated virus vaccine platform for development of an expression vaccine. Traditionally such vaccines have exhibited higher immunogenicity and AAV in particular has yielded very durable responses. The AAV-based vaccines will be tested for immunogenicity and are for the ability to elicit toxin-neutralizing antibodies, as well as for use in concert with soluble protein immunogens. Finally, the most promising constructs of both soluble protein and expressed forms will be tested in anthrax spore inhalation challenge studies in rabbits. Such experiments have been extensively validated against primate experiments previously and also appear to correlate most closely with human anthrax disease and protection. Through this approach we will develop promising candidate anthrax vaccines that can protect against currently existing strains of anthrax as well as new and enhanced threats based on engineered forms of anthrax.
吸入性炭疽已成为一种重大和持续的生物战和生物恐怖主义威胁。 虽然疫苗策略已经基本上控制了动物群体中的这种疾病,但目前的疫苗策略仍然是有效的。 被许可用于人类使用的疫苗具有几个缺点,包括显著的不良反应和低 免疫原性导致需要多次免疫。炭疽感染的生物学和 特别是其毒素的作用已经在分子和细胞水平上被优雅地阐明。这 提供了一个独特的机会,合理设计和开发一种改进的疫苗, 目前的炭疽以及未来可能遇到的改良形式。 在这个项目中,我们将使用大量的知识和洞察力有关炭疽毒素 开发分子靶向疫苗,以预防感染后毒素的灾难性影响。 基于对晶体结构的仔细分析,序列,以及对所有组分的功能研究, 炭疽毒素,我们将开发可溶性蛋白疫苗,直接抗体反应对关键的 参与毒素活化、组装和粘附细胞的蛋白质片段。我们将测试这些疫苗 这些构建体具有引发强抗体应答的能力以及中和体内毒素活性的能力, 体外测定。基于对可溶性蛋白质构建体的响应的分析,将选择的构建体与可溶性蛋白质构建体进行比较。 转移到腺相关病毒疫苗平台,用于开发表达疫苗。 传统上,此类疫苗表现出更高的免疫原性,特别是AAV产生了非常高的免疫原性。 持久的反应。将测试基于AAV的疫苗的免疫原性,并测试其引发免疫应答的能力。 毒素中和抗体,以及与可溶性蛋白免疫原一起使用。最后 最有希望的可溶性蛋白质和表达形式的构建体将在炭疽孢子中进行测试 兔吸入激发研究。这种实验已经在灵长类动物身上得到了广泛的验证 以前的实验,也似乎与人类炭疽病最密切相关, 保护通过这种方法,我们将开发出有希望的候选炭疽疫苗, 针对现有的炭疽菌株以及基于工程的新的和增强的威胁, 炭疽的形式。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.
显示来自保护性抗原的环中和决定簇的重组疫苗完全保护兔子免受实验性吸入炭疽的侵害。
  • DOI:
    10.1128/cvi.00612-12
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Oscherwitz,Jon;Yu,Fen;Jacobs,JanaL;Cease,KempB
  • 通讯作者:
    Cease,KempB
Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.
  • DOI:
    10.1016/j.vaccine.2015.03.037
  • 发表时间:
    2015-05-11
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Oscherwitz J;Quinn CP;Cease KB
  • 通讯作者:
    Cease KB
Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.
人用佐剂中的针对表位的肽免疫原可以保护兔子免受实验性吸入性炭疽病的侵害。
  • DOI:
    10.1016/j.vaccine.2014.11.042
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Oscherwitz,Jon;Feldman,Daniel;Yu,Fen;Cease,KempB
  • 通讯作者:
    Cease,KempB
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kemp Bailey Cease其他文献

Kemp Bailey Cease的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kemp Bailey Cease', 18)}}的其他基金

Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
  • 批准号:
    8391150
  • 财政年份:
    2010
  • 资助金额:
    $ 101.09万
  • 项目类别:
Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
  • 批准号:
    8597331
  • 财政年份:
    2010
  • 资助金额:
    $ 101.09万
  • 项目类别:
Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
  • 批准号:
    8212753
  • 财政年份:
    2010
  • 资助金额:
    $ 101.09万
  • 项目类别:
Epitope-specific vaccines targeting the alpha toxin of Staphylococcus aureus
针对金黄色葡萄球菌α毒素的表位特异性疫苗
  • 批准号:
    8045558
  • 财政年份:
    2010
  • 资助金额:
    $ 101.09万
  • 项目类别:
Molecularly Targeted Vaccines for Anthrax
炭疽分子靶向疫苗
  • 批准号:
    7025796
  • 财政年份:
    2003
  • 资助金额:
    $ 101.09万
  • 项目类别:
Molecularly Targeted Vaccines for Anthrax
炭疽分子靶向疫苗
  • 批准号:
    6838737
  • 财政年份:
    2003
  • 资助金额:
    $ 101.09万
  • 项目类别:
Molecularly Targeted Vaccines for Anthrax
炭疽分子靶向疫苗
  • 批准号:
    6787799
  • 财政年份:
    2003
  • 资助金额:
    $ 101.09万
  • 项目类别:
Molecularly Targeted Vaccines for Anthrax
炭疽分子靶向疫苗
  • 批准号:
    6690634
  • 财政年份:
    2003
  • 资助金额:
    $ 101.09万
  • 项目类别:
ADJUVANT STRATEGIES USING T CELL HELP ENHANCER PEPTIDES
使用 T 细胞帮助增强肽的佐剂策略
  • 批准号:
    3547529
  • 财政年份:
    1989
  • 资助金额:
    $ 101.09万
  • 项目类别:
RATIONAL PEPTIDE COMPONENT VACCINES FOR AIDS
艾滋病合理肽成分疫苗
  • 批准号:
    3140806
  • 财政年份:
    1989
  • 资助金额:
    $ 101.09万
  • 项目类别:

相似海外基金

A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis
治疗囊性纤维化患者 CFTR 调节剂治疗不良反应的个性化方法
  • 批准号:
    MR/X00094X/1
  • 财政年份:
    2022
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Research Grant
Identifying genetic polymorphisms and elucidating polygenic architecture associated with adverse reactions due to rituximab
识别遗传多态性并阐明与利妥昔单抗不良反应相关的多基因结构
  • 批准号:
    22K15910
  • 财政年份:
    2022
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mechanistic study of sulfa drug-induced severe cutaneous adverse reactions by focusing on HLA-A*11:01
以HLA-A*为重点的磺胺类药物致严重皮肤不良反应机制研究11:01
  • 批准号:
    22K06738
  • 财政年份:
    2022
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Studentship Programs
Significance of gamma-chain in severe cutaneous adverse reactions
伽马链在严重皮肤不良反应中的意义
  • 批准号:
    19K17779
  • 财政年份:
    2019
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Historical sociology of adverse reactions related to vaccination in Japan
日本疫苗接种不良反应的历史社会学
  • 批准号:
    18K00267
  • 财政年份:
    2018
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
SEARCH(加拿大医疗保健不良反应的主动监测和评估)
  • 批准号:
    379425
  • 财政年份:
    2018
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Operating Grants
IGF::OT::IGF SBIR Phase II: Topic 338 - Predictive Biomarkers of Adverse Reactions to Prostrate Cancer Radiotherapy
IGF::OT::IGF SBIR II 期:主题 338 - 前列腺癌放射治疗不良反应的预测生物标志物
  • 批准号:
    9576448
  • 财政年份:
    2017
  • 资助金额:
    $ 101.09万
  • 项目类别:
Development of in silico prediction method for idiosyncratic adverse reactions associated with HLA genotypes
与 HLA 基因型相关的特殊不良反应的计算机预测方法的开发
  • 批准号:
    16K15156
  • 财政年份:
    2016
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Characterising the Immune Response to Drugs That Cause Idiosyncratic Adverse Reactions
表征对引起特殊不良反应的药物的免疫反应
  • 批准号:
    367156
  • 财政年份:
    2016
  • 资助金额:
    $ 101.09万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了